Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
A one‐point ALI increase was associated with MCI conversion odds by 15%.
Why it matters
In 385 people with mild cognitive impairment, a one-point increase in allostatic load index was associated with 15% higher odds of conversion to mild dementia due to Alzheimer's disease. This is an observational association and does not test any treatment, cure or prevention.
-
Alzheimer’s disease (AD) is a heterogeneous neurodegenerative disorder in which tau neurofibrillary tangles are a pathological hallmark closely associated with cognitive dysfunction and neurodegeneration.
Why it matters
Using tau PET scans and deep learning, this study identified two subpopulations of Alzheimer's patients, one with higher global tau burden but similar cognition to the other group. This describes disease heterogeneity and does not test or propose a treatment or cure.
-
Alzheimers disease (AD) represents the most prevalent form of dementia, affecting millions worldwide and posing significant public health challenges.
Why it matters
This systematic review examines imaging methods such as MRI, PET, DTI and arterial spin labeling for detecting Alzheimer's disease early, including hippocampal atrophy on structural MRI and amyloid-PET for visualizing protein aggregates. It reviews diagnostic tools and does not itself test any treatment, cure or prevention.
-
Research interest in the application of electroencephalogram (EEG) as a non-invasive diagnostic tool for the automated detection of neurodegenerative diseases is growing.
Why it matters
This paper presents an open-access EEG dataset from 88 participants with Alzheimer's disease, frontotemporal dementia and healthy controls, recorded during photic stimulation. It is a data resource for developing and validating automated classification algorithms, not a treatment, cure or prevention.
-
Delirium is a common cause and complication of hospitalization in the elderly and is associated with higher risk of future dementia and progression of existing dementia, of which 70% is Alzheimer's disease (AD).
Why it matters
This review discusses how artificial intelligence could aid drug discovery for delirium and Alzheimer's disease, from target identification to therapy development. It reports no tested treatment, cure, or prevention and notes the absence of effective treatments.
-
In this paper, we propose a deep super-resolution generative adversarial network (DSR-GAN) combined with a convolutional neural network (CNN) model designed to classify four stages of Alzheimer's disease (AD): Mild Dementia (MD), Moderate Dementia (MOD), Non-Demented (ND), and Very Mild Dementia (VMD).
Why it matters
This study describes a computer model combining image enhancement and a neural network to classify four stages of Alzheimer's disease from MRI images with high reported accuracy. It is a technical classification study and does not test any treatment, cure, or prevention.
-
The results of gene set enrichment and gene set variation analyses indicated that immune-related pathways were upregulated in patients with VaD.
Why it matters
This bioinformatics and animal study found that immune-related pathways were upregulated in vascular dementia and that RAC1 and CMTM5 mRNA were reduced in a mouse model. The authors state these findings pave the way for exploring mechanisms, but no treatment or prevention is tested.
-
weighted MRI can assess macro-structural brain atrophy, diffusion tensor imaging (DTI) unveils these hidden microstructural alterations.
Why it matters
This study describes a computer-aided diagnosis framework using diffusion tensor imaging features to distinguish Alzheimer's disease, mild cognitive impairment, and normal controls. The authors describe these as promising preliminary results from a small subset of participants, and the work is about diagnosis rather than treatment.
-
Alzheimer disease (AD)-modifying therapies are approved for treatment of early-symptomatic AD.
Why it matters
This study used data from the Dominantly Inherited Alzheimer Network to estimate how many participants would be needed in clinical trials using cognitive, imaging, and cerebrospinal fluid outcomes in autosomal dominant Alzheimer's disease. It provides planning information for future trials and does not itself test any treatment.
-
KL -VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.
Why it matters
In 223 participants across the Alzheimer's continuum, associations between KLOTHO-VS heterozygosity and higher cerebrospinal fluid Aβ42 and Aβ42/40 ratio were non-significant overall, except when restricted to APOE ε4 carriers. This is observational biomarker research and does not show that KLOTHO-VS heterozygosity or α-Klotho protein treats or prevents Alzheimer's disease.
-
-values compared to gait features. Linear regression analysis indicated that turn dynamics had stronger correlations with executive function and working memory, suggesting a more pronounced relationship between cognitive performance and turn features than gait variables.
Why it matters
This study found that turn dynamics during a dual-task walking test were more sensitive for detecting cognitive impairment than straight walking metrics and correlated with executive function and working memory. Incorporating turning movements into gait analysis could improve diagnosis, but no treatment is tested.
-
44/100
and amyloid composite in the context of AD.
Why it matters
Blood hepcidin and NfL had limited value for diagnosing Alzheimer's disease but combining them was informative for vascular dementia. This is a diagnostic finding and does not address treating, curing or preventing Alzheimer's disease.
-
44/100
Alzheimer disease (AD) is the most common type of dementia and one of the leading causes of death in elderly patients.
Why it matters
This review discusses shared biological pathways, such as the APOE E4 allele and neuroinflammation, that may link chemotherapy-related cognitive impairment and Alzheimer's disease. It proposes possible reasons some chemotherapy patients may be at higher risk but reports no treatment or prevention tested in patients.
-
The left inferior parietal lobule (IPL)_6_5 (rostroventral area 39) showed the best ability to discriminate between patients with AD and those with CN (AUC = 0.688).
Why it matters
This study found that specific subregions of the parietal lobe, particularly the angular gyrus, could help discriminate between Alzheimer's disease and normal cognition and predict progression from normal cognition to MCI and from MCI to Alzheimer's disease. The authors suggest early detection of volume changes in these regions may be useful in identifying disease tendency and its treatment, but no treatment was tested.
-
Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive.
Why it matters
This retrospective cohort study investigated how CSF t-tau, p-tau181 and Aβ1-42 relate to cognitive scores in patients with probable frontotemporal dementia and Alzheimer's disease in a memory clinic. It concerns biomarker-cognition associations, not treating, curing or preventing Alzheimer's disease.
-
Amyloid-targeting therapy has recently become widely available in the United States for the treatment of patients with symptomatic mild Alzheimer disease (AD).
Why it matters
This case series of 6 patients on lecanemab found varied changes in cerebral blood flow on arterial spin-labeling MRI, with some cases showing increased flow and cognitive improvement and others showing no substantial change or cognitive decline. The authors present this as a potential longitudinal biomarker of treatment response, but the small number of cases means it is preliminary.
-
Participants recognized the added value of DCAs, and multiple factors were identified as facilitators and barriers for their use.
Why it matters
These focus groups identified facilitators and barriers to using digital cognitive assessments, including test motivation, digital suitability and user-friendliness. Participants recognised added value of these assessments for early recognition; the study does not test any treatment, cure or prevention.
-
; 95% CI: 1.01, 1.04). Neighborhood environment features, such as higher air pollution levels, were associated with higher neighborhood ADRD incidence.
Why it matters
This study found that neighborhood features such as higher air pollution levels were linked to higher neighborhood rates of Alzheimer's disease and related dementias in South Carolina. It does not test any treatment or prevention, so it cannot show whether reducing pollution would lower dementia risk.
-
Burden of chronic intravenous treatments exceed the gross medical and social care cost savings and value of caregiver benefit.
Why it matters
Comparing five hypothetical disease-modifying treatments with equal efficacy and safety, chronic bi-weekly intravenous infusion had the highest direct medical cost and caregiver burden and reduced treatment value by 44%, while oral treatment reduced treatment value by only 2%. Because the treatments compared were hypothetical and assumed equally effective, this work addresses how administration route and monitoring affect cost and caregiver burden, not whether any treatment works.
-
It is imperative to recognize and mitigate persistent disparities in the COVID‐19 pandemic, particularly pertaining to participation in long‐COVID research.
Why it matters
This study analyzed screening and enrollment data from a multi-racial SARS-CoV-2 cohort being evaluated with 7-Tesla MRI and cognitive assessments for Alzheimer's disease and related dementias. It found that non-White race and higher Area Deprivation Index were independently associated with higher likelihood of non-response to research participation.
-
Quantification results using the proposed deep learning-based method showed stronger correlations with the FreeSurfer estimates than SPM-based SN using MRI did.
Why it matters
A deep learning method quantified amyloid brain PET scans without needing an MRI, with results closely matching FreeSurfer-based estimates. This is a technical tool for analyzing scans and does not itself treat, cure or prevent Alzheimer disease.
-
Using amyloid PET imaging as a single primary surrogate efficacy measure in Alzheimer's disease immunotherapy trials, as happened when the FDA granted accelerated approval of aducanumab, is unjustified.
Why it matters
This paper argues that using amyloid PET as a single primary surrogate measure in Alzheimer's immunotherapy trials is unjustified because PET quantification of amyloid can be distorted and misrepresent treatment effects. It calls for rigorous evidence that proposed treatments are clinically effective and safe before approval.
-
Alzheimer's disease (AD) is a chronic neurodegenerative disease characterised by cognitive impairment, behavioural alteration, and functional decline.
Why it matters
This review summarises that over 130 Alzheimer's disease-associated susceptibility loci have been identified, with variants enriched in immune-related genes including TREM2. It is a genomics review and does not report any treatment, cure, or prevention for Alzheimer's disease.
-
Identifying individuals at risk for progression of AD dementia could potentially help to personalize disease management to plan future care.
Why it matters
This systematic review found a considerable rise in research using machine learning on clinical data to model risk for progression of Alzheimer's disease dementia. It is a review of prediction methods and does not test any treatment, cure or prevention.
-
The county clusters with the highest and lowest AD mortality rates were in Washington (WA) and New York (NY), respectively, with other notable high-mortality clusters on the border of Tennessee, Georgia, and Alabama as well as in North Dakota and South Dakota.
Why it matters
This study found stable geographic disparities in Alzheimer's disease mortality across U.S. counties from 1999 to 2018, with the highest rates in Washington and lowest in New York. It does not explain the causes of these disparities or provide information on treating, curing, or preventing the disease.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
- Seeing the trees in the wood: the importance of co-pathologies in Alzheimer’s disease and dementia with Lewy bodies
- Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging
- Neurobiological and therapeutic landmarks of depression associated with Alzheimer’s disease dementia
- Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
- Alzheimer's disease
- Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease (Cochrane review)
- Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions
- Neutrophil hyperactivation correlates with Alzheimer's disease progression
- Markers of Left Atrial Myopathy: Prognostic Usefulness for Ischemic Stroke and Dementia in People in Sinus Rhythm